Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility of Autologous Induced Pluripotent Stem Cells of Cardiac Lineage in Subjects With Congenital Heart Disease

NCT05647213 is registered in ClinicalTrials.gov with HeartWorks, Inc. as lead sponsor.

NCT NCT05647213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05647213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility of Autologous Induced Pluripotent Stem Cells of Cardiac Lineage in Subjects With Congenital Heart Disease
Lead sponsor
HeartWorks, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 3, 2023
Completion date
February 28, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congenital heart disease, heart failure nyha class iii, heart failure nyha class iv, univentricular heart